Pardes Biosciences is a biopharmaceutical company that aims to find new therapeutics to help patients with life-threatening diseases. Their primary focus is on their lead candidate, the PBI-0451, which is currently in clinical development to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and their associated diseases. Pardes Biosciences was incorporated in 2020 and is based in Carlsbad, California.